Secondary hyperparathyroidism in chronic renal disease – etiopathogenesis, diagnosis and treatment

Mileta Poskurica; Mina Poskurica; Dejan Petrović

doi:10.2298/7384

Mileta Poskurica Department of Urology and Nephrology, Clinical Center Kragujevac, Kragujevac, Serbia; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
Mina Poskurica Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia
Dejan Petrović Department of Urology and Nephrology, Clinical Center Kragujevac, Kragujevac, Serbia; Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia

DOI: https://doi.org/10.2298/7384

Keywords: kidney failure, chronic, hyperparathyroidism, secondary, diagnostic techniques and procedures, therapeutics,

Abstract

References

Levey AS, de Jong PE, Coresh J, El-Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011; 80(1): 17−28.

Bricker NS. On the pathogenesis of the uremic state. An expo-sition of the "trade-off hypothesis". N Engl J Med 1972; 286(20): 1093−9.

Poskurica M. Imbalance of phosphate, calcium and magnesium ions in development of chronic renal failure [dissertation]. Bel-grade: School of Medicine, University of Belgrade; 1993. (Ser-bian)

Lewin E, Rodriguez M. Abnormal parathyroid gland function in CKD. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 77−108.

Naveh-Many T, Silver J. Regulation of parathyroid hormone bio-synthesis and gene expression. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 61–75.

Poskurica M. Dynamics of fractional phosphate excretion in chronic renal failure [thesis]. Belgrade: School of Medicine, University of Belgrade; 1989.

Ureña P, Olgaard K, Martin K. Biochemical markers of bone metabolism in CKD. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 173−98.

Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70(4): 654−9.

Gonzaley AE, Martin JK. Growth factors and cytokines in renal bone disease. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 137−44.

Ott MS. New aspects of normal bone biology. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 15−30.

Petrovic D, Stojimirovic B. Secondary hyperparathyroidism: risk factor for development of cardiovascular complications in pa-tients on hemodialysis. Med Pregl 2010; 63(9−10): 674−80. (Serbian)

Poskurica M, Lazarević M, Petrović D, Lazarević T, Milošević J. Cal-cium and Phosphate Disturbances and its Regulating Hor-mones in Chronic Renal Failure. XXXVI Congress of EDTA-ERA, EDTA-ERA; Spain, Madrid; September 5–8: 1999; Abstract 38.

Petrović D, Obrenović R, Trbojević-Stanković J, Majkić-Singh N, Stojimirović B. Hyperphosphatemia - The Risk Factor for Ad-verse Outcome in Maintenance Hemodialysis Patients. J Med Biochem 2012; 31(3): 239−45. (Serbian)

Cañadillas S, Canalejo A, Santamaría R, Rodríguez ME, Estepa JC, Martín-Malo A, et al. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Am Soc Nephrol 2005; 16(7): 2190−7.

Koizumi M, Komaba H, Fukagawa M. Parathyroid Function in Chronic Kidney Disease: Role of FGF23-Klotho Axis. In: Razzaque MS, editor. Phosphate and Vitamin D in Chronic Kidney Disease. Basel: Karger; 2013. p. 110−23.

Lewin E, Garfia B, Almaden Y, Rodriguez M, Olgaard K. Autore-gulation in the parathyroid glands by PTH/PTHrP receptor li-gands in normal and uremic rats. Kidney Int 2003; 64(1): 63−70.

Levy J, Morgan J, Brown E. Complications of ESRD: renal bone disease. In: Levy J, Morgan J, Brown E. Oxford handbook of di-alysis. 2nd ed. New York: Oxford University Press; 2007. p. 653−82.

Poskurica M. Renal osteodystrophy in patients on peritoneal di-alysis. In: Nešić V, editor. Peritoneal dialysis: A clinical problem. Belgrade: Faculty of Medicine; 2003. p. 167−95. (Serbian, English)

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagno-sis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; (113): S1-130.

National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1−201.

Poskurica M, Lazarević M, Grubor M, Laković S, Mitrović N, Milošević J. Metastatic calcification of the heart in patients with terminal renal failure. Medicinska istraživanja 1999; 13(2): 109−13. (Serbian)

Applbaum YH. Imaging of the skeleton snd the joints in CKD. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 199−216.

D'Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, et al. A multicenter study on the effects of lantha-num carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; (85): S73−8.

Poskurica M. The importance of vitamin D in preventing pro-gression and complications of terminal renal failure. In: Stolic R, editor. School of dialysis Leskovac, "Preventive Nephrolo-gy. Nis: University of Nis; 2004. p. 229−36. (Serbian)

Park J, Rhee CM, Lau WL, Kalantar-Zadeh K. Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol 2014; 12(2): 306−12.

Cunningham J, Lewin E, Silver J. Medical therapy in chronic kid-ney disease. In: Olgaard K, Salusky BI, Silver J, editors. The spec-trum of Mineral and Bone Disorders in Chronic Kidney Dis-ease. 2nd ed. Oxford: University Press; 2010. p. 463−83.

Nemeth EF. Calcimimetics and calcilytics in the treatment of chronic kidney disease-mineral and bone disorder. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 443−61.

Argilés A, Mourad G. How do we have to use the calcium in the dialysate to optimize the management of secondary hyperpara-thyroidism? Nephrol Dial Transplant 1998; 13 Suppl 3: 62−4.

Sarfati E, Drueke BT. Surgical management of secondary hyperparathroidism. In: Olgaard K, Salusky BI, Silver J, editors. The spectrum of Mineral and Bone Disorders in Chronic Kidney Disease. 2nd ed. Oxford: University Press; 2010. p. 543−59.

Ogata H, Koiwa F, Shishido K, Takahashi K, Ito H, Kinugasa E, et al. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodia-lysis patients with secondary hyperparathyroidism. Ther Apher Dial 2007; 11(3): 202−9.